Tags

Type your tag names separated by a space and hit enter

The nasal decongestant effect of xylometazoline in the common cold.

Abstract

BACKGROUND

Xylometazoline is a nasal decongestant spray that constricts nasal blood vessels and increases nasal airflow, enabling patients with a blocked nose to breathe more easily. The purpose of this study was to characterize objectively and subjectively the decongestant and additional effects of xylometazoline in the common cold.

METHODS

A double-blind, placebo-controlled, parallel group study was performed. Patients with a common cold (n = 61) were treated with xylometazoline 0.1% (n = 29) or placebo (saline solution; n = 32; 1 spray three times a day for up to 10 days). The primary objective was to determine the decongestant effect (nasal conductance); the secondary objectives were to determine the peak subjective effect (visual analog scale), duration of relief of nasal congestion, total and individual cold symptoms and general well-being (patients' daily diary), and adverse events (AEs).

RESULTS

The decongestant effect of xylometazoline was significantly greater than placebo, as shown by the nasal conductance at 1 hour (384.23 versus 226.42 cm(3)/s; p <or= 0.0001) and peak subjective effect (VAS, 20.7 mm versus 31.5 mm; p = 0.0298). Nasal conductance was significantly superior for up to 10 hours (p = 0.0009) and there was a trend in favor of xylometazoline for up to 12 hours (not statistically significant). Xylometazoline significantly improved total and some individual common cold symptoms scores (p < 0.05), leading to significantly greater patient general evaluation and satisfaction with treatment (p < 0.05). Nineteen AEs were reported: 8 with xylometazoline (all mild-moderate) and 11 with placebo (1 severe).

CONCLUSION

Xylometazoline is an effective and well-tolerated decongestant nasal spray that significantly relieved nasal congestion compared with placebo in the common cold and provided long-lasting relief with just 1 spray, helping patients to breathe more easily for a longer period of time.

Links

Authors+Show Affiliations

,

Common Cold Centre & Healthcare Clinical Trials, Cardiff University, Cardiff, United Kingdom. eccles@cardiff.ac.uk

, ,

Source

MeSH

Administration, Intranasal
Adrenergic alpha-Agonists
Adult
Common Cold
Dose-Response Relationship, Drug
Double-Blind Method
Female
Follow-Up Studies
Humans
Imidazoles
Male
Nasal Decongestants
Patient Satisfaction
Retrospective Studies
Treatment Outcome

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18655753

Citation

Eccles, Ronald, et al. "The Nasal Decongestant Effect of Xylometazoline in the Common Cold." American Journal of Rhinology, vol. 22, no. 5, 2008, pp. 491-6.
Eccles R, Eriksson M, Garreffa S, et al. The nasal decongestant effect of xylometazoline in the common cold. Am J Rhinol. 2008;22(5):491-6.
Eccles, R., Eriksson, M., Garreffa, S., & Chen, S. C. (2008). The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology, 22(5), pp. 491-6. doi:10.2500/ajr.2008.22.3202.
Eccles R, et al. The Nasal Decongestant Effect of Xylometazoline in the Common Cold. Am J Rhinol. 2008;22(5):491-6. PubMed PMID: 18655753.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The nasal decongestant effect of xylometazoline in the common cold. AU - Eccles,Ronald, AU - Eriksson,Margareta, AU - Garreffa,Steve, AU - Chen,Shirley C, Y1 - 2008/07/24/ PY - 2008/7/29/pubmed PY - 2008/11/15/medline PY - 2008/7/29/entrez SP - 491 EP - 6 JF - American journal of rhinology JO - Am J Rhinol VL - 22 IS - 5 N2 - BACKGROUND: Xylometazoline is a nasal decongestant spray that constricts nasal blood vessels and increases nasal airflow, enabling patients with a blocked nose to breathe more easily. The purpose of this study was to characterize objectively and subjectively the decongestant and additional effects of xylometazoline in the common cold. METHODS: A double-blind, placebo-controlled, parallel group study was performed. Patients with a common cold (n = 61) were treated with xylometazoline 0.1% (n = 29) or placebo (saline solution; n = 32; 1 spray three times a day for up to 10 days). The primary objective was to determine the decongestant effect (nasal conductance); the secondary objectives were to determine the peak subjective effect (visual analog scale), duration of relief of nasal congestion, total and individual cold symptoms and general well-being (patients' daily diary), and adverse events (AEs). RESULTS: The decongestant effect of xylometazoline was significantly greater than placebo, as shown by the nasal conductance at 1 hour (384.23 versus 226.42 cm(3)/s; p <or= 0.0001) and peak subjective effect (VAS, 20.7 mm versus 31.5 mm; p = 0.0298). Nasal conductance was significantly superior for up to 10 hours (p = 0.0009) and there was a trend in favor of xylometazoline for up to 12 hours (not statistically significant). Xylometazoline significantly improved total and some individual common cold symptoms scores (p < 0.05), leading to significantly greater patient general evaluation and satisfaction with treatment (p < 0.05). Nineteen AEs were reported: 8 with xylometazoline (all mild-moderate) and 11 with placebo (1 severe). CONCLUSION: Xylometazoline is an effective and well-tolerated decongestant nasal spray that significantly relieved nasal congestion compared with placebo in the common cold and provided long-lasting relief with just 1 spray, helping patients to breathe more easily for a longer period of time. SN - 1050-6586 UR - https://www.unboundmedicine.com/medline/citation/18655753/The_nasal_decongestant_effect_of_xylometazoline_in_the_common_cold_ L2 - https://medlineplus.gov/coldandcoughmedicines.html DB - PRIME DP - Unbound Medicine ER -